Lyra Therapeutics shares moved higher in premarket trading Tuesday after the clinical-stage biotechnology company reported a successful Phase 2 study of its LYR-220 drug candidate in the inflammatory sinus disease chronic rhinosinusitis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,